Evidence map›Paper›PMID 42898187›Full record

ReviewBioImpacts : BI2026

RNA vaccines in motion: A multidisciplinary exploration of design, delivery, and deployment.

Qamar Abuhassan, Ahmed Aldulaimi, O S Waleed, Subbulakshmi Ganesan, V Kavitha, Laxmidhar Maharana, Renu Sharma, Mutabar Latipova, Nazira Madatova, Doniyor Jumanazarov and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioImpacts : BI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qamar AbuhassanDepartment of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, University of Jordan, Amman, 11942, Jordan.ORCID https://orcid.org/0000-0002-1038-6483
Ahmed AldulaimiDepartment of Pharmacy, Al-Zahrawi University, Karbala, Iraq.
O S WaleedMedical Laboratory Technique College, The Islamic University, Najaf, Iraq.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, JAIN (Deemed-to-be University), Bangalore, Karnataka, India.
V KavithaDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Laxmidhar MaharanaDepartment of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.
Renu SharmaDepartment of Chemistry, University Institute of Sciences, Chandigarh University, Mohali, Punjab, India.
Mutabar LatipovaUniversity of Tashkent for Applied Sciences, Str. Gavhar 1, Tashkent 100149, Uzbekistan.
Nazira MadatovaThe Department of Pharmaceutical and Chemistry, Alfraganus University, Tashkent, 100190, Uzbekistan.
Doniyor JumanazarovUrgench State University, Kh. Alimdjan str. 14, Urgench 220100, Uzbekistan.
Aseel SmeratFaculty of Educational Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA vaccines represent a major advance in prophylactic and therapeutic vaccinology, largely due to the success of nucleoside-modified mRNA vaccines encapsulated in lipid nanoparticles (LNPs) during the COVID-19 pandemic. These platforms build on long-standing progress in RNA chemistry, immunology, and nanotechnology. This review concentrates primarily on molecular design (codon/sequence optimization, chemical modifications, and data-driven antigen selection) and delivery optimization (LNPs and emerging alternatives like virus-like particles, extracellular vesicles, and ligand-targeted systems). Clinical progress is highlighted through examples from oncology, including personalized neoantigen approaches, combination therapies, and immunopeptidomics-guided validation, as well as early preclinical work on tolerance induction and localized protein replacement. Overall, continued refinement of RNA sequence engineering and delivery systems positions these platforms as flexible tools for rapid-response vaccination and therapy, especially where fast antigen adaptation and scalable production are required.

Indexed as

Chemical modificationCodon optimizationLipid nanoparticlesmRNARNA vaccinesSelf amplifying RNA

Identifiers

PMID42898187
PMCPMC13677338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.